Author Identifier
Marc Sim: https://orcid.org/0000-0001-5166-0605
Document Type
Journal Article
Publication Title
Aging Clinical and Experimental Research
Volume
37
Issue
1
PubMed ID
40120052
Publisher
Springer
School
Nutrition and Health Innovation Research Institute / School of Medical and Health Sciences
Publication Unique Identifier
10.1007/s40520-025-02995-9
RAS ID
78270
Funders
National Institute of Aging of the National Institute of Health (R01 AG071663, P30DK056350-23) / CIBERFES (CB16/10/00477) / Instituto de Salud Carlos III / Ministerio de Ciencia e Innovación / European Regional Development Fund
Abstract
The Global Leadership Initiative in Sarcopenia (GLIS) aims to standardize the definition and diagnostic criteria for sarcopenia into one unifying, common classification. Among other actions to achieve this objective, the GLIS has organized three different working groups (WGs), with the WG on outcomes of sarcopenia focusing on reporting its health outcomes to be measured in clinical practice once a diagnosis has been established. This includes sarcopenia definitions that better predict health outcomes, the preferred tools for measuring these outcomes, and the cutoffs defining normal and abnormal values. The present article synthesizes discussions and conclusions from this WG, composed of 13 key opinion leaders from different continents worldwide. Results rely on systematic reviews, meta-analyses, and relevant cohort studies in the field. With a high level of evidence, sarcopenia is significantly associated with a reduced quality of life, a higher risk of falls and fractures and a higher risk of mortality. Sarcopenia has been moderately associated with a higher risk of reduced instrumental activities of daily living (IADL). However, the GLIS WG found only inconclusive level of evidence to support associations between sarcopenia and higher risks of hospitalization, nursing home admission, mobility impairments, and reduced basic activities of daily living (ADL). This limitation underscores the scarcity of longitudinal studies, highlighting a barrier to understanding its progression and implications over time.
DOI
10.1007/s40520-025-02995-9
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Comments
Beaudart, C., Alcazar, J., Aprahamian, I., Batsis, J. A., Yamada, Y., Prado, C. M., ... & Global Leadership Initiative in Sarcopenia (GLIS) group. (2025). Health outcomes of sarcopenia: a consensus report by the outcome working group of the Global Leadership Initiative in Sarcopenia (GLIS). Aging Clinical and Experimental Research, 37. https://doi.org/10.1007/s40520-025-02995-9